Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received a consensus rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $25.75.
ATRA has been the subject of several recent research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a report on Monday. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Finally, BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd.
Shares of Atara Biotherapeutics (ATRA) traded up 3.77% during midday trading on Friday, reaching $15.15. The company’s stock had a trading volume of 159,686 shares. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00. The stock’s 50-day moving average is $14.74 and its 200 day moving average is $15.87. The stock’s market capitalization is $462.97 million.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.05). On average, analysts expect that Atara Biotherapeutics will post ($3.89) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thestockobserver.com/2017/09/12/brokerages-set-atara-biotherapeutics-inc-atra-pt-at-25-75.html.
In other news, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $15.02, for a total value of $66,088.00. Following the sale, the chief executive officer now directly owns 737,767 shares in the company, valued at approximately $11,081,260.34. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total value of $75,900.00. Following the completion of the sale, the executive vice president now owns 368,080 shares in the company, valued at $4,656,212. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,509 shares of company stock valued at $726,242. Insiders own 16.10% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $132,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $185,000. Voya Investment Management LLC grew its stake in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,651 shares during the period. American International Group Inc. grew its stake in shares of Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 948 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at approximately $252,000. Institutional investors own 82.95% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.